| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 508,820 | 249,380 | 204,040 | 180,080 | 793,740 |
| Sales Growth | +104.03% | +22.22% | +13.31% | -77.31% | +1,093.41% |
| Net Income | -67,090 | -506,980 | -557,520 | -644,090 | 313,880 |
| Net Income Growth | +86.77% | +9.07% | +13.44% | -305.20% | +190.28% |
Blueprint Medicines Corp
(BPMC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Blueprint Medicines Corporation is a biopharmaceutical company focused on developing the potentially transformational precision medicines to address patients with genomically defined cancers and rare diseases.
Fiscal Year End Date: 12/31